PROCEPT BioRobotics Corporation increased revenue guidance for full year 2024. For the period, the Company projects revenue for the full year 2024 to be $213.5 million, which represents 57% growth over the Company?s prior year revenue. This compares to previous revenue guidance of $210.0 million.
PROCEPT BioRobotics Corporation
Equities
PRCT
US74276L1052
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
59.92 USD | -0.37% |
|
-5.14% | +42.97% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.97% | 3.08B | |
-3.95% | 184B | |
-0.90% | 109B | |
-2.27% | 68.87B | |
+15.24% | 46.61B | |
-6.00% | 46.39B | |
+5.36% | 40.74B | |
+20.65% | 31.26B | |
-5.50% | 24.24B | |
+11.60% | 24B |
- Stock Market
- Equities
- PRCT Stock
- News PROCEPT BioRobotics Corporation
- Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024